Home Dicerna™ Pharmaceuticals

Dicerna™ Pharmaceuticals

Dicerna™ Announces Closing of Agreement With Novo Nordisk

As previously announced on Nov. 18, 2019, Dicerna and Novo Nordisk entered into an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology.